Ascendis Pharma A/S (NASDAQ:ASND) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a hold rating in a report issued on Saturday morning.

Several other brokerages have also commented on ASND. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Stifel Nicolaus lifted their price objective on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Finally, Cantor Fitzgerald increased their target price on Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $256.71.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $204.40 on Friday. Ascendis Pharma A/S has a 52-week low of $118.03 and a 52-week high of $219.30. The company has a market capitalization of $12.61 billion, a PE ratio of -39.61 and a beta of 0.44. The business’s fifty day moving average is $201.86 and its 200 day moving average is $184.71.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 55 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ascendis Pharma A/S by 1.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 58 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock worth $2,103,000 after purchasing an additional 73 shares during the period. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the period. Finally, Main Management ETF Advisors LLC raised its holdings in Ascendis Pharma A/S by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 96 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.